论文部分内容阅读
目的探究老年肺癌患者血清低密度脂蛋白(LDL)与细胞角蛋白19片段(CYFRA21-1)含量及其相关性,并探讨其在临床工作中的意义。方法选择2015年4月至2016年6月期间华北理工大学附属医院呼吸内科及心胸外科诊治的门诊及住院的202例老年肺癌患者设为肺癌组,并按照是否化疗分为未化疗组(n=94)和化疗组(n=108)。另选择门诊老年健康体检者80例作为正常对照组。采用化学沉淀法检测血清LDL水平,采用放射免疫法检测血清CYFRA21-1水平,比较所有受试者血清LDL、CYFRA21-1含量。并在未化疗组中比较不同病理类型肺癌患者血清LDL、CYFRA21-1含量,分析未化疗组肺癌患者血清中LDL与CYFRA21-1之间的相关性。结果肺癌组患者总体血清LDL、CYFRA21-1含量均高于对照组(P均<0.01)。未化疗组肺癌患者血清LDL含量与化疗组比较差异无统计学意义(P>0.05),血清CYFRA21-1含量高于化疗组(P<0.01)。未化疗组及化疗组肺癌患者血清LDL、CYFRA21-1含量均高于对照组(P均<0.01)。未化疗组不同病理类型肺癌患者血清LDL、CYFRA21-1含量差异无统计学意义(P均>0.05)。未化疗组肺癌患者血清LDL水平与CYFRA21-1水平具有相关性(r=0.512,P<0.05)。结论肺癌患者存在血脂代谢紊乱,血清CYFRA21-1的高水平与肺癌疾病进展情况密切相关,检测肺癌患者的血清LDL与CYFRA21-1水平在肺癌诊断与治疗中具有重要临床意义。
Objective To investigate the correlation between serum low density lipoprotein (LDL) and cytokeratin 19 fragment (CYFRA21-1) in elderly patients with lung cancer and to explore its significance in clinical practice. Methods A total of 202 elderly patients with lung cancer undergoing outpatient and inpatient department of Respiratory Medicine and Cardiothoracic Surgery at Affiliated Hospital of North China University of Technology from April 2015 to June 2016 were selected as lung cancer group and were divided into non-chemotherapy group (n = 94) and chemotherapy group (n = 108). Another 80 out-patient elderly health examination as a normal control group. Serum LDL levels were determined by chemical precipitation method. Serum levels of CYFRA21-1 were detected by radioimmunoassay. Serum levels of LDL and CYFRA21-1 were compared among all the subjects. The serum levels of LDL and CYFRA21-1 in lung cancer patients with different pathological types were compared in the non-chemotherapy group, and the correlation between LDL and CYFRA21-1 levels in serum of non-chemotherapy lung cancer patients was analyzed. Results The serum levels of LDL and CYFRA21-1 in lung cancer patients were significantly higher than those in control group (all P <0.01). Serum LDL levels in patients with lung cancer without chemotherapy were not significantly different from those in chemotherapy group (P> 0.05). Serum levels of CYFRA21-1 in patients with lung cancer were higher than those in chemotherapy group (P <0.01). The levels of serum LDL and CYFRA21-1 in non-chemotherapy group and chemotherapy group were higher than those in control group (all P <0.01). The levels of serum LDL and CYFRA21-1 in lung cancer patients with different pathological types of non-chemotherapy group had no significant difference (all P> 0.05). Serum LDL levels in patients with lung cancer without chemotherapy were correlated with CYFRA21-1 levels (r = 0.512, P <0.05). Conclusion There is a disorder of lipid metabolism in patients with lung cancer. The high level of serum CYFRA21-1 is closely related to the progression of lung cancer. Detection of serum LDL and CYFRA21-1 levels in patients with lung cancer has important clinical significance in the diagnosis and treatment of lung cancer.